Shin Mukai

About the Expert

Dr. Shin Mukai completed his Bachelor's and Master's degrees in Chemistry at Kyoto University in Japan. He obtained a PhD degree in Bio-Organic Chemistry at The University of Western Australia. During his first postdoctoral assignment at the Keio University School of Medicine in Japan, he engaged in biology and immunology research, creating novel and patented treatments of chronic Graft-Versus-Host Disease. He then took up his second postdoctoral position at Brigham and Womens Hospital/Harvard Medical School and worked on macrophage activation and heterogeneity with a goal of developing new therapies for coronary heart disease. He is extremely passionate about applying his expertise in synthetic organic/medicinal chemistry and biology/immunology to cancer research. In 2022, he obtained a certificate for Entrepreneurship Essentials from Harvard Business School and co-founded the oncology pharmaceutical company New Wind Therapeutics, L3C in the US as Chief Executive Officer and Chief Scientific Officer.